- LDS
- /Medical Tests
- /ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
Diseases (6)Access to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
OverviewAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
Clinical UtilityAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
InterpretationAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
Reference RangesAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
MethodologyAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
Turnaround TimeAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
CPTAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
LOINCAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
ICD10Access to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
Additional ICD10Access to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.
ReferencesAccess to ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS is restricted.